Maria Paris Selected Research

Infections

9/2023	Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet's Syndrome.
11/2022	Safety of Apremilast in Patients with Psoriasis and Psoriatic Arthritis: Findings from the UK Clinical Practice Research Datalink.
8/2016	Rates of Cancers and Opportunistic Infections in Patients With Psoriatic Arthritis Compared With Patients Without Psoriatic Arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maria Paris Research Topics

Disease

14	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2024 - 12/2015
10	Psoriatic Arthritis 09/2023 - 12/2015
5	Oral Ulcer (Mouth Ulcer) 02/2022 - 11/2019
5	Nausea 01/2022 - 11/2019
5	Headache (Headaches) 01/2022 - 11/2019
4	Neoplasms (Cancer) 09/2023 - 08/2016
4	Pain (Aches) 09/2023 - 09/2021
4	Diarrhea 01/2022 - 11/2019
3	Infections 09/2023 - 08/2016
3	Cardiovascular Diseases (Cardiovascular Disease) 09/2023 - 12/2015
3	Respiratory Tract Infections (Respiratory Tract Infection) 01/2022 - 08/2020
2	Nasopharyngitis 01/2022 - 08/2020
1	Opportunistic Infections (Opportunistic Infection) 09/2023
1	Pruritus (Itching) 09/2023
1	Melanoma (Melanoma, Malignant) 11/2022
1	Tachycardia (Tachyarrhythmias) 11/2022
1	Vasculitis (Vasculitides) 11/2022
1	Hematologic Neoplasms (Hematological Malignancy) 11/2022
1	Ankylosing Spondylitis 01/2022
1	Hyperlipidemias (Hyperlipidemia) 02/2021
1	Hypertension (High Blood Pressure) 02/2021
1	Obesity 02/2021
1	Vomiting 07/2020
1	Tuberculosis (Tuberculoses) 01/2020
1	Herpes Zoster 01/2020
1	Hepatitis C 01/2020
1	Skin Neoplasms (Skin Cancer) 08/2016
1	Persistent Infection 03/2006
1	Reinfection 03/2006
1	Otitis Media 03/2006

Drug/Important Bio-Agent (IBA)

21	apremilastIBA 01/2024 - 07/2018
2	Phosphodiesterase 4 InhibitorsIBA 10/2023 - 02/2020
2	omega-Chloroacetophenone (Mace)IBA 09/2023 - 12/2015
2	Antirheumatic Agents (DMARD)IBA 01/2022 - 07/2018
1	Type 4 Cyclic Nucleotide PhosphodiesterasesIBA 10/2021
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2020
1	insulin receptor-related receptor (IRR)IBA 08/2016
1	Cefdinir (Omnicef)FDA LinkGeneric 03/2006
1	SuspensionsIBA 03/2006
1	Penicillins (Penicillin)FDA Link 03/2006

Therapy/Procedure

5	Therapeutics 01/2024 - 07/2020
1	Contraindications 02/2023
1	Injections 11/2022